Chugai Pharmaceutical Co., Ltd.’s Evrysdi (risdiplam) is among the latest batch of new drug approvals in Japan, providing another option for spinal muscular atrophy (SMA) patients in the country. The survival motor neuron 2 (SMN2)-directed splicing modifier was granted orphan designation in March 2019 and filed for approval last October.
Latest Japan Approvals Include Evrysdi For SMA
Plus Global First For Imeglimin
Japan's latest batch of product approvals includes the country's second therapy for SMA and the first nod globally for a novel antidiabetic.
More from Japan
More from Asia
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
South Korea announces planned revisions to a government scheme to designate "innovative" biopharma companies amid allegations of "discrimination" against foreign firms.